Systematic review shows robot-assisted minimally invasive esophagectomy reduces blood loss and hospital stay compared to conventional minimally invasive approaches for resectable esophageal cancer cases involving adult patients

This systematic review and meta-analysis evaluates the comparative efficacy and safety of robot-assisted minimally invasive esophagectomy versus conventional minimally invasive esophagectomy in adult patients undergoing surgery for resectable esophageal cancer. The analysis pooled data from 13,321 patients to assess a broad spectrum of clinical outcomes, ranging from blood loss and conversion rates to long-term mortality and specific complication profiles. The study design encompasses various surgical techniques, acknowledging the substantial heterogeneity inherent in pooling data from predominantly non-randomized studies. This heterogeneity significantly impacts the precision of effect estimates and introduces potential concerns regarding publication bias across different outcome measures.

Regarding perioperative metrics, the data suggests distinct advantages for the robotic approach. Patients undergoing robot-assisted procedures experienced significantly lower blood loss and a reduced likelihood of requiring conversion to open surgery. Furthermore, the total lymph node yield was higher, as was the harvest of left recurrent laryngeal nerve lymph nodes. These findings suggest that the enhanced visualization and dexterity provided by robotic systems may facilitate more meticulous dissection in complex anatomical regions. Consequently, pulmonary complications were fewer, and overall postoperative morbidity was lower in the robotic cohort. Additionally, intensive care unit stays and total hospital durations were shorter, indicating a potentially smoother immediate recovery trajectory for patients treated with the robotic platform.

Despite these promising short-term operational metrics, the analysis reveals no statistically significant differences between the two techniques regarding critical long-term outcomes. Operative time was consistently longer with the robotic approach, likely reflecting the learning curve associated with mastering the new technology. Crucially, there was no significant difference in the rate of R0 resection, which is vital for oncological clearance. Similarly, rates of anastomotic leak, recurrent laryngeal nerve palsy, cardiac complications, chyle leak, and surgical site infection did not differ significantly between the groups. Most importantly, both 30-day and 90-day mortality rates showed no significant disparity, suggesting that the robotic approach does not compromise patient survival in the short term.

The certainty of the evidence across these key outcomes is rated as very low. This low rating stems primarily from the predominance of non-randomized studies included in the meta-analysis. Such observational designs are susceptible to selection bias and confounding factors that randomized controlled trials would mitigate. Furthermore, the substantial heterogeneity across the pooled analyses complicates the interpretation of results, as variations in surgical expertise, institutional protocols, and patient populations can skew the aggregated data. Outcome-specific concerns regarding imprecision and potential publication bias further erode confidence in the definitive conclusions drawn from this body of literature.

In terms of practice relevance, the findings suggest that robot-assisted minimally invasive esophagectomy is a safe alternative to conventional minimally invasive esophagectomy. While there is no clear evidence of increased major morbidity or short-term mortality, the procedure may offer tangible short-term perioperative advantages. Surgeons should weigh these potential benefits against the longer operative times and the current limitations of the evidence base. The decision to adopt robotic technology should be informed by the specific context of the surgical center, the surgeon's experience level, and the individual needs of the patient. Until higher-quality randomized data becomes available, the choice between techniques remains a nuanced clinical decision rather than a definitive guideline.

Clinicians must interpret these results with caution, recognizing that the current data does not definitively establish superiority for one technique over the other. The observed reductions in blood loss and hospital stay are encouraging but must be viewed within the context of very low certainty. Future research should prioritize randomized controlled trials to address the limitations of existing evidence and provide more robust data on long-term oncological outcomes. Until then, the robotic approach represents a viable option that may enhance specific perioperative metrics without compromising safety or survival, provided that the associated challenges of longer operative times and learning curves are managed effectively.